Blackhawk’s MindBio Therapeutics Announces Completion of First Phase 1 Microdosing Clinical Trial

Successful completion of Phase 1 clinical trials

MindBio remains the only organization in the world to successfully receive government approvals for a physician to prescribe LSD (lysergic acid diethylamide) to patients to take the drug unsupervised in the community in the same way as any other drug

Phase 1 clinical trial report and safety data are being analyzed and will be announced shortly

Phase 2 clinical trials currently in development

MindBio spin-out plans are progressing as planned

Vancouver, British Columbia – TheNewswire – May 3, 2022 – Blackhawk Growth Corp. BLR; BLR; BLRZF; (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics (“MindBio”) has completed its 12-month Phase 1 clinical trial of microdosing LSD in 80 healthy participants.

MindBio is developing a microdosing regimen with LSD for the treatment of mental disorders such as depression. To bring these new treatments to market, MindBio must prove the safety and efficacy of the treatment through a rigorous clinical trial process.

The Phase 1 clinical trial is the largest safety trial of its kind ever completed under a randomized, double-blind, placebo-controlled discipline, the results of which will support the development of MindBio’s intellectual property and progress toward commercialization of treatments for mental illness.

MindBio looks forward to analyzing the data from the Phase 1 clinical trial to further inform the planned Phase 2 clinical trials.

MindBio is working to create a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in primary care. In larger doses, LSD is a hallucinogenic drug that significantly alters cognition, thinking, mood and perception, but in much smaller “microdoses” the drug is subperceptual, meaning patients can take the drug without noticing the hallucinogenic effects, yet still have the medicinal effects. operation and go about their normal day.

MindBio is working to become the first to market by bringing to market a microdosing regimen with significant potential benefits to global mental health.

“We are proud of the incredible work of our scientific team and the completion of this amazing milestone as we move towards developing breakthrough treatments for mental illness,” said Frederick Pels, CEO of Blackhawk.

MindBio continues to make progress toward the previously announced spinout that it expects to complete upon receipt of all necessary approvals, including approval from Blackhawk’s shareholders. The MindBio spinout is expected to create significant shareholder value as every Blackhawk shareholder will receive shares in MindBio upon completion of the spinout.

About Blackhawk Growth

Blackhawk is an investment holding company that aims to create substantial value for its shareholders through the acquisition and development of high-growth companies. It has focused its investments on the health, cannabis and cannabidiol industries in both Canada and the United States. The portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics, Digital Mind Therapeutics, Blum Distributors Ltd and an equity position in Gaia Grow Corp GAIA.

The company is diligently posting updates via videos from the company’s official YouTube channel

Join the conversation on our Blackhawk group supporters’ telegram group at and visit us online at

For more information, please contact:

Frederick Pels, Chief Executive Officer


Warning Regarding Forward-Looking Statement:

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transactions and future activities of MindBio Therapeutics Pty Ltd. The company provides forward-looking statements for the purpose of conveying information about current expectations and plans regarding the future and readers are cautioned that such statements may not be appropriate for other purposes. This information is inherently subject to risks and uncertainties that may be general or specific that give rise to the possibility that any expectations, predictions, forecasts, projections or conclusions may prove incorrect, assumptions may not be correct and objectives , strategic goals and priorities will not be achieved. These risks and uncertainties include, but are not limited to, those identified and reported in the Company’s public filings under the Company’s SEDAR profile at While the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that could cause actions, events or results not to be as expected, estimated or meant. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

This post Blackhawk’s MindBio Therapeutics Announces Completion of First Phase 1 Microdosing Clinical Trial was original published at “”

Leave a Reply

Your email address will not be published.